...We Welcome You To The Resverlogix HUB In The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Message: 15,000 @ $2.93

The reason for paying the premium instead of buying on the open market is that the shares purchased at premium are immediately deliverable thereby satisfying the delivery failure the premium paying purchaser has incurred. 

New Message
Please login to post a reply